Investigational drug · Phase 3
ICP-248
Also called: Mesutoclax
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed or Refractory Mantle Cell Lymphoma (MCL), Acute Myeloblastic Leukemia, Relapsed/Refractory Marginal Zone Lymphoma (MZL).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
8
Any phase or sponsor naming "ICP-248"
First trial start
2024
May 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ICP-248", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Acute Myeloblastic Leukemia
- Relapsed/Refractory Marginal Zone Lymphoma (MZL)
- Hematologic Malignancies
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "ICP-248" as an intervention, largest first.
- A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07925190 · 318 participants (planned) · Start Nov 3, 2026 · Primary completion Dec 2029
Drug: Mesutoclax (ICP-248); Azacitidine (AZA) and 1 more · For: Acute Myeloblastic Leukemia
Sites: Hangzhou, China
- Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaPivotal-lookingNot yet recruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07896590 · 292 participants (planned) · Start Oct 2026 · Primary completion Oct 2028
Drug: Orelabrutinib; ICP-248 · For: Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Sites: Bozhou, China; Hefei, China; Beijing, China · 46 sites in all
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Pivotal-lookingNot yet recruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07784101 · 280 participants (planned) · Start Oct 2026 · Primary completion Oct 2032
Drug: ICP-248; Pirtobrutinib and 1 more · For: Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Sites: Hefei, China; Beijing, China; Chongqing, China · 24 sites in all
- ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid MalignanciesRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT06656494 · 266 participants (planned) · Start Dec 18, 2024 · Primary completion Jun 2027
Drug: ICP-248; Azacitidine · For: Acute Myelogenous Leukemia; Myelodysplastic Syndromes (MDS)
Sites: Orange, California; New Haven, Connecticut; Tampa, Florida · 22 sites in all
- ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)Pivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT06378138 · 226 participants (planned) · Start May 15, 2024 · Primary completion Nov 25, 2030
Drug: ICP-248; Orelabrutinib · For: Hematologic Malignancies
Sites: Bengbu, China; Hefei, China; Beijing, China · 53 sites in all
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT05728658 · 191 participants (planned) · Start Mar 9, 2023 · Primary completion Aug 30, 2025
Drug: ICP-248; ICP-248 and 5 more · For: Hematological Malignancies
Sites: Bengbu, China; Hefei, China; Beijing, China · 22 sites in all
InnoCare Pharma Inc.Industry
NCT06351527 · 78 participants (planned) · Start Apr 23, 2024 · Primary completion Jun 25, 2027
Drug: ICP-248; Obinutuzumab (G) and 1 more · For: Mature B-cell Malignancies
Sites: Plantation, Florida; Westbury, New York; San Juan, Puerto Rico · 8 sites in all
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07082686 · 75 participants (planned) · Start Aug 21, 2025 · Primary completion Dec 2027
Drug: ICP-248 · For: Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Sites: Hefei, China; Beijing, China; Chengdu, China · 29 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- OrelabrutinibICP-022Phase 311 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.